Equities analysts expect Transenterix Inc (NASDAQ:TRXC) to report sales of $870,000.00 for the current quarter, according to Zacks. Two analysts have made estimates for Transenterix’s earnings, with the highest sales estimate coming in at $1.68 million and the lowest estimate coming in at $60,000.00. Transenterix reported sales of -$999.00 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 100.1%. The firm is expected to issue its next earnings report on Friday, August 4th.

According to Zacks, analysts expect that Transenterix will report full year sales of $870,000.00 for the current fiscal year, with estimates ranging from $6.26 million to $8.26 million. For the next year, analysts expect that the firm will post sales of $33.78 million per share, with estimates ranging from $16.60 million to $49.90 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Transenterix.

A number of equities research analysts have commented on the stock. B. Riley downgraded shares of Transenterix to a “neutral” rating and set a $0.70 price objective on the stock. in a research report on Tuesday, May 16th. Zacks Investment Research downgraded shares of Transenterix from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th.

Shares of Transenterix (NASDAQ TRXC) traded up 10.6420% during midday trading on Friday, reaching $0.6893. 662,712 shares of the company’s stock traded hands. The stock’s market capitalization is $102.38 million. The firm’s 50-day moving average price is $0.56 and its 200 day moving average price is $1.07. Transenterix has a 1-year low of $0.45 and a 1-year high of $2.33.

In other news, Director Richard C. Pfenniger, Jr. acquired 100,000 shares of the company’s stock in a transaction on Tuesday, May 16th. The shares were bought at an average cost of $0.54 per share, with a total value of $54,000.00. Following the transaction, the director now owns 148,000 shares in the company, valued at approximately $79,920. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/09/transenterix-inc-nasdaqtrxc-expected-to-post-quarterly-sales-of-870000-00.html.

Transenterix Company Profile

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Get a free copy of the Zacks research report on Transenterix (TRXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.